Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1985
http://purl.obolibrary.org/obo/NCIT_C1985
|
|---|---|
| Preferred Name | Sipuleucel-T |
| Definitions |
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05) |
|---|---|
| prefLabel | Sipuleucel-T
|
| label | Sipuleucel-T
|
| PDQ_Closed_Trial_Search_ID | 38038
|
| code | C1985
|
| Has_Target | |
| prefixIRI | NCIT:C1985
|
| in_subset |
See more
See less
|
| Display_Name | Sipuleucel-T
|
| Preferred_Name | Sipuleucel-T
|
| FDA_UNII_Code | 8Q622VDR18
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Sipuleucel-T
|
| CAS_Registry | 917381-47-6
|
| NSC Number | 720270
|
| NCI_Drug_Dictionary_ID | 38038
|
| Legacy Concept Name | APC8015_Vaccine
|
| type | |
| ALT_DEFINITION | A drug used to treat prostate cancer that has spread. It is made from immune system cells collected from a patient with prostate cancer. The cells are treated with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Provenge is a type of vaccine and a type of cellular adoptive immunotherapy.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38038
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
Cell
|
| UMLS_CUI | C1706668
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |